Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as kanamycin is eliminated unchanged predominantly via glomerular filtration and there is little potential for interaction with emtricitabine and tenofovir via competition for active renal transport mechanisms. However, both kanamycin and tenofovir-DF are potentially nephrotoxic and emtricitabine/tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of emtricitabine/tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be closely monitored.
Use of emtricitabine/tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product like aminoglycosides.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
Coadministration of Truvada with drugs that are eliminated by active tubular secretion may increase concentrations of FTC, tenofovir, and/or the coadministered drug. Some examples include, but are not limited to, aminoglycosides.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking